Previous 10 | Next 10 |
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given the Prevalence of Pre-Existing Gastrointestinal Disorders Among Those Prescribed Trudhesa ...
2023-05-18 10:04:28 ET Gainers: Enveric Biosciences ( ENVB ) +68% . Alimera Sciences ( ALIM ) +35% . Corvus Pharmaceuticals ( CRVS ) +12% . Viracta Therapeutics ( VIRX ) +11% . Bullfrog AI Holdings ( BFRG ) +8% . Losers: N...
2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...
2023-05-15 13:13:19 ET Gainers: Ohmyhome Limited ( OMH ) +169% . NeoGames ( NGMS ) +112% . GSI Technology ( GSIT ) +36% . Vaxart ( VXRT ) +34% . WiSA Technologies ( WISA ) +35% . Scilex Holding Company ( SCLX ) +31% ....
2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....
2023-05-12 11:33:06 ET Impel Pharmaceuticals Inc. (IMPL) Q1 2023 Earnings Conference Call May 12, 2023, 08:30 AM ET Company Participants Adrian Adams - Chairman and Chief Executive Officer Michael Kalb - Chief Financial Officer Leonard Paolillo - Chief Commercial...
2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...
2023-05-12 08:24:21 ET Impel NeuroPharma press release ( NASDAQ: IMPL ): Q1 GAAP EPS of -$1.27 misses by $0.49 . Revenue of $4.37M (+142.8% Y/Y) misses by $0.63M . For further details see: Impel NeuroPharma GAAP EPS of -$1.27 misses by $0.49, revenue of $...
Trudhesa ® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -...
2023-05-10 08:35:57 ET Impel Pharmaceuticals ( NASDAQ: IMPL ) appoints Michael W. Kalb, CPA, as CFO, effective May 10, 2023. Mr. Kalb has more than 30 years of experience in the pharmaceutical and financial service industries. Prior to joining Impel Pharmaceuticals, h...
News, Short Squeeze, Breakout and More Instantly...
Impel Pharmaceuticals Inc. Company Name:
IMPL Stock Symbol:
NASDAQ Market:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Impel Pharmaceuticals Inc. (IMPL) is expected to report for Q3 2023
2023-10-05 09:39:40 ET DENVER, Colo., Oct 5, 2023 ( www.247marketnews.com )- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) stated, this morning, that it is exploring strategic alternatives and plans to consider a wide range of options with a focus on maximizing shareholder value, including ...